Beschreibung:
<jats:title>ABSTRACT</jats:title>
<jats:p>
Moxifloxacin is the most active fluoroquinolone against
<jats:italic>Mycobacterium tuberculosis</jats:italic>
in vitro. However, data about the efficacy in patients are not available. We enrolled 17 patients with tuberculosis in a prospective, randomized study. After 5 days of monotherapy with either moxifloxacin or isoniazid, we detected significant decreases in mean CFU per milliliter in sputum in both groups. The calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log
<jats:sub>10</jats:sub>
CFU per ml of sputum per day, respectively. According to the data from our study, moxifloxacin exhibits an early bactericidal activity that is comparable to that of isoniazid.
</jats:p>